Stay updated with breaking news from Second Closing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT is made and entered into as of May 31, 2024 by and among Bionomics Limited, a public company incorporated under...
YANDEX N.V. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On February 4, 2024, Yandex N.V. , the...
Investegate announcements from Allotment and issue of Second Tranche Shares
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company Highlights Durable s
Investegate announcements from Proposed Fundraise to progress Therapeutics